Stada Arzneimittel AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Stada Arzneimittel AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 15.63 billion Danish Kroner [US$2.45 billion]
of which 19%
was Other Pharmaceuticals),
Hikma Pharmaceuticals PLC
of the United Kingdom
(£1.45 billion [US$1.89 billion]
of which 40%
was Injectable Pharmaceuticals), and
based in France
(1.67 billion Euro [US$1.95 billion]
of which 76%
was Specialty Care).
Stada Arzneimittel AG reported sales of 2.14 billion Euro (US$2.49 billion)
December of 2016.
a very small
increase of 1.1%
versus 2015, when the company's sales were 2.12 billion Euro.
Sales at Stada Arzneimittel AG have increased during each of the previous five years
(and since 2011, sales have increased a total of 25%).
Sales of Generics saw an increase
that was more than double the company's growth rate: sales were up
5.2% in 2016, from
1.22 billion Euro to 1.28 billion Euro.
Not all segments of Stada Arzneimittel AG experienced an increase in sales in 2016:
sales of Group Holding Company/other fell 98.9% to 1,000.00 Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).